ImmuCell Corporation (ICCC)
| Market Cap | 63.10M |
| Revenue (ttm) | 21.14M |
| Net Income (ttm) | 1.10M |
| Shares Out | 7.74M |
| EPS (ttm) | 0.14 |
| PE Ratio | 59.49 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,066 |
| Open | 8.58 |
| Previous Close | 8.50 |
| Day's Range | 8.13 - 8.59 |
| 52-Week Range | 7.30 - 10.96 |
| Beta | 0.67 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | May 12, 2022 |
About ICCC
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, ...
Financial Performance
In 2021, ImmuCell's revenue was $19.24 million, an increase of 25.43% compared to the previous year's $15.34 million. Losses were -$78,292, -92.34% less than in 2020.
Financial StatementsNews
ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
PORTLAND, Maine, May 19, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientificall...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2022
Q1 2022 Product Sales Increased 46% over Q1 2021 Q1 2022 Product Sales Increased 46% over Q1 2021
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2022
Conference Call Scheduled for Friday, May 13, 2022 at 9:00 AM ET Conference Call Scheduled for Friday, May 13, 2022 at 9:00 AM ET
UPDATE -- Dr. Mark Wustenberg joins ImmuCell as Commercial Leader of Stakeholder Engagement
PORTLAND, Maine, May 05, 2022 (GLOBE NEWSWIRE) -- Certain immaterial corrections have been made to the second and fifth paragraphs.
Dr. Mark Wustenberg joins ImmuCell as Commercial Leader of Stakeholder Engagement
PORTLAND, Maine, May 05, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientificall...
ImmuCell Announces Record Preliminary, Unaudited Sales Results for First Quarter of 2022
PORTLAND, Maine, April 11, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifica...
ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2021
Annual Product Sales for 2021 Increased 25% over 2020 Annual Product Sales for 2021 Increased 25% over 2020
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2021
Conference Call Scheduled for Wednesday, February 23, 2022 at 9:00 AM ET Conference Call Scheduled for Wednesday, February 23, 2022 at 9:00 AM ET
ImmuCell Announces Record Preliminary, Unaudited Sales Results for the Year Ended December 31, 2021
PORTLAND, Maine, Jan. 05, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifical...
ImmuCell Announces Unaudited Financial Results for the Third Quarter Ended September 30, 2021
Q3 2021 Net Income of $148,000 versus Q3 2020 Net Loss of ($323,000) Q3 2021 Net Income of $148,000 versus Q3 2020 Net Loss of ($323,000)
ImmuCell to Announce Unaudited Financial Results for the Third Quarter Ended September 30, 2021
Conference Call Scheduled for Tuesday, November 16, 2021 at 9:00 AM ET Conference Call Scheduled for Tuesday, November 16, 2021 at 9:00 AM ET
ImmuCell Announces Record Preliminary, Unaudited Sales Results for Third Quarter of 2021
PORTLAND, Maine, Oct. 06, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifical...
Raffael Lichdi, DVM Joins ImmuCell's Sales & Marketing Team
PORTLAND, Maine, Sept. 14, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifica...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmuCell Corporation - ICCC
New York, New York--(Newsfile Corp. - September 2, 2021) - Pomerantz LLP is investigating claims on behalf of investors of ImmuCell Corporation ("ImmuCell" or the "Company") (NASDAQ: ICCC). Such investo...
ImmuCell Required to Prepare Second Submission of Final Major Technical Section for Re-Tain®
PORTLAND, Maine, Aug. 24, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifical...
ImmuCell Announces Unaudited Financial Results for the Second Quarter Ended June 30, 2021
Bottom Line: Q2 2021 Net Income of $141,000 versus Q2 2020 Net Loss of ($766,000) Bottom Line: Q2 2021 Net Income of $141,000 versus Q2 2020 Net Loss of ($766,000)
ImmuCell to Announce Unaudited Financial Results for the Second Quarter Ended June 30, 2021
Conference Call Scheduled for Friday, August 13, 2021 at 9:00 AM ET Conference Call Scheduled for Friday, August 13, 2021 at 9:00 AM ET
ImmuCell Announces Strong Preliminary, Unaudited Sales Results for Second Quarter of 2021
PORTLAND, Maine, July 07, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifical...
ImmuCell Announces Unaudited Financial Results for the First Quarter Ended March 31, 2021
PORTLAND, Maine, May 13, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientificall...
ImmuCell to Announce Unaudited Financial Results for the First Quarter Ended March 31, 2021
Conference Call Scheduled for Friday, May 14, 2021 at 9:00 AM ET Conference Call Scheduled for Friday, May 14, 2021 at 9:00 AM ET
ImmuCell Closes $4,250,000 Equity Financing
PORTLAND, Maine, April 14, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifica...
ImmuCell Announces Preliminary, Unaudited Sales Results for First Quarter of 2021
PORTLAND, Maine, April 07, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifica...
ImmuCell Makes Important Regulatory Submission and Announces Unaudited Financial Results for the Year Ended December ...
PORTLAND, Maine , Feb. 22, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifica...
ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2020
Conference Call Scheduled for Tuesday, February 23, 2021 at 9:00 AM ET Conference Call Scheduled for Tuesday, February 23, 2021 at 9:00 AM ET
ImmuCell Announces Restructuring of its Bank Debt
PORTLAND, Maine, Dec. 15, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifical...